Methods of manufacturing a cannabinoid product can involve extracting from raw cannabis plant material an extract including cannabinoids and terpenes; separating the extract into a cannabinoid rich fraction and a terpene rich fraction; subjecting the terpene rich fraction to heating in a microwave oven thereby to distil terpene components from the terpene rich fraction; collecting the terpene components. In some embodiments, at least one of the terpene components can be recombined with at least one cannabinoid from the cannabinoid rich fraction. Preferably, the heating step is carried out while subjecting the terpene rich fraction to a vacuum. The cannabinoid rich fraction is processed by crystallisation and recrystallisation to produce a purified acidic cannabinoid component, wherein the purified acidic cannabinoid component can remain carboxylated or be decarboxylated is combined with said at least one terpene component. The recombined cannabinoid product can exhibit characteristics closer to those of the original plant.

The present invention is related to preparations containing one or more anthocyanins for use in the prevention and treatment of cardiovascular diseases and reduction of arterial stiffness in a subject.

An extract of Melastoma dodecandrum Lour. for treating ulcerative colitis (UC), a preparation method therefor and use thereof are provided, relating to the technical field of biomedicine. The method for preparing the extract of Melastoma dodecandrum Lour. of the present disclosure includes: soaking Melastoma dodecandrum Lour. in water, followed by heating to boiling, performing a reflux condensation and filtration, and collecting a filtrate, which constitutes the extract of Melastoma dodecandrum Lour.

A method of producing ginseng concentrate includes passing a ginseng extract through a composite adsorbent to produce a ginseng extract treated with the composite adsorbent, adding cyclodextrin mixture powder to the prepared ginseng extract treated with the composite adsorbent followed by stirring, allowing to stand, and filtering, and concentrating the filtered ginseng extract, and also a ginseng concentrate produced by the method.

Described is a method of reducing or eliminating chlorophyll content in a plant extract, while retaining certain other active components of said extract, by exposing said plant extract to a UV-C light source. Also described are extracts having lower levels of chlorophyll while retaining levels of certain other active components, such as cannabinoids and terpenes.

The present disclosure provides use of an effective part extract of Monochasma savatieri in preparation of a drug for treating an inflammatory disease or a tumor. In the present disclosure, an effective part of Monochasma savatieri is separated and purified by various separation and purification methods (including solvent extraction, macroporous resin column chromatography, MCI column separation, and Sephadex LH-20 gel column separation) separately, to obtain the effective part extract of Monochasma savatieri. The effective part extract of Monochasma savatieri is capable of significantly inhibiting secretion of TNF-, and significantly inhibiting proliferation of breast cancer cells and lung cancer cells, thereby effectively treating the inflammatory disease or the tumor. The present disclosure provides a favorable theoretical basis for finding a drug that can effectively treat the inflammatory disease or the tumor from the Monochasma savatieri, which is of great significance to development of novel drugs.

A method for producing a plant-based extract composition having the effect of enhancing nutrition and immunity comprises the following steps: (i) preparing materials; (ii) creating a base mixture; (iii) creating a foundation mixture; (iv) creating a first temporary mixture; (v) creating a second temporary mixture; (vi) creating a uniform mixture; (vii) creating a post-incubation mixture; and (viii) concentrating the post-incubation to obtain the plant-based extract composition having the effect of enhancing nutrition and immunity. This composition includes the following components: Ngoc Linh ginseng (Panax vietnamensis) extract; jiaogulan (Gynostemma pentaphyllum) powder; maingay's tree (Cratoxylum maingayi) powder; nodding clubmoss (Lycopodiella cernua) powder; red ginseng (Radix Ginseng Rubra) powder; codonopsis root (Codonopsis pilosula) powder; angelica root (Angelica sinensis) powder; rice bran oil, legume powder; coenzyme Q10; ginsenoside Rb1 extract; and honey.

The present invention describes a method which outlines a process for conversion of CBD to a .sup.9-tetrahydrocannabinol (.sup.9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the .sup.9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% .sup.9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce .sup.9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% .sup.9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the .sup.9-THC using distillation and collecting an essentially pure fraction of .sup.9-THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity .sup.9-THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.

A method for extracting 3,5-O-dicaffeoylquinic acid from Huangshan Gongju and its application in drugs for protecting against alcoholic liver damage. The 3,5-O-dicaffeoylquinic acid has the following structural formula:

##STR00001##

The present disclosure selects the medicinal and edible homology plant, Huangshan Gongju, as the research object. This plant is abundant in resources and the raw materials are easy to obtain. Specifically, the present disclosure uses 70% ethanol to extract Huangshan Gongju, uses the method of bioactivity-guided isolation, and uses a FLA-2025-10-120A preparative liquid chromatograph to isolate a phenolic compound from the active site of Gongju that resists alcoholic liver damage. The compound separation method is simple, quick, and easy to operate.

The present disclosure describes a method which outlines a process for conversion of CBD to a .sup.9-tetrahydrocannabinol (.sup.9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the .sup.9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% .sup.9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce .sup.9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% .sup.9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the .sup.9-THC using distillation and collecting an essentially pure fraction of .sup.9-THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity .sup.9-THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.